Using U-500 Insulin
April 17, 2012 By
The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
April 16, 2012 By
IN BRIEF Although the number of diabetes treatments has substantially increased in the past two decades, today's therapies are considered far from ideal. Yet, what constitutes an ideal therapy is not readily clear, as diabetes drug therapies are regularly judged both by their effects on glycemia and by a wide variety of nonglycemic metrics. This review describes the characteristics of an ideal diabetes therapy from the perspective of patients, physicians, payors, and financial analysts and examines how well currently available therapies and several late-stage candidates meet these guideposts. … [Read more...]
A New Challenge for Safe Ordering of U-500 Insulin: Electronic Medicine Reconciliation
April 16, 2012 By
A Perspective on Principles of Comparative Cost-Effectiveness Studies for Pharmacotherapy of Chronic Diseases
April 16, 2012 By
IN BRIEF Comparative cost-effectiveness drug studies can support decision-making for allocation of health care resources if principles of clinical pharmacology and pharmacoepidemiology are considered. Use of constant or milligram-equivalent doses instead of bio-equivalent doses, reliance on placebo-controlled instead of head-to-head randomized trials, disparities in community-based distribution of disease burden, lack of clinically important endpoint data, and absence of adherence data can limit the applicability of such studies. This article highlights methodological issues that should be incorporated in comparative cost-effectiveness drug studies, using statins as an example. … [Read more...]
Use of A1C for Screening and Diagnosis of Type 2 Diabetes in Three Rural Health Care Systems
April 16, 2012 By
Management of Type 2 Diabetes: What Is the Next Step After Metformin?
April 16, 2012 By
